Welcome to our dedicated page for Cyclacel Phar Pr SEC filings (Ticker: CYCCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio Green Med Solution, formerly Cyclacel Pharmaceuticals, files regulatory reports that document a completed shift from a clinical-stage biopharmaceutical issuer to a diversified company engaged primarily in fire safety protection and distribution activities. The filings describe the acquisition of Fitters Sdn. Bhd., the liquidation of the former U.K. subsidiary, and the sale of the Plogosertib drug.
Its SEC record also includes Form 8-K disclosures on operating results, Regulation FD materials, quarterly cash dividend declarations on 6% Convertible Exchangeable Preferred Stock, Nasdaq listing-rule notices for the preferred stock, and proxy materials for annual-meeting governance and shareholder voting matters.
Ong Yee Lung reports beneficial ownership of 20.76% of Cyclacel Pharmaceuticals, Inc.'s common stock class. The filing states he holds an aggregate of 872,000 instruments comprised of 218,000 common shares and three series of warrants — 218,000 Series A, 218,000 Series B and 218,000 Series C — each exercisable into common stock. The filing indicates sole voting and dispositive power over the aggregate amount and affirms the holdings were not acquired to change or influence control of the issuer.
Ong Yee Lung reports beneficial ownership of 20.76% of Cyclacel Pharmaceuticals, Inc.'s common stock class. The filing states he holds an aggregate of 872,000 instruments comprised of 218,000 common shares and three series of warrants — 218,000 Series A, 218,000 Series B and 218,000 Series C — each exercisable into common stock. The filing indicates sole voting and dispositive power over the aggregate amount and affirms the holdings were not acquired to change or influence control of the issuer.
Kua Khai Loon reports beneficial ownership of 872,000 shares of Cyclacel Pharmaceuticals, Inc., representing 20.76% of the outstanding common stock. The reported ownership is composed of 218,000 shares of common stock and 218,000 warrants in each of three series (Series A, B and C), each exercisable into common stock, for a total of 872,000 underlying shares. The filing certifies the holdings were not acquired to change or influence control of the issuer. The report includes links to the amended and restated warrant forms as exhibits.
Kua Khai Loon reports beneficial ownership of 872,000 shares of Cyclacel Pharmaceuticals, Inc., representing 20.76% of the outstanding common stock. The reported ownership is composed of 218,000 shares of common stock and 218,000 warrants in each of three series (Series A, B and C), each exercisable into common stock, for a total of 872,000 underlying shares. The filing certifies the holdings were not acquired to change or influence control of the issuer. The report includes links to the amended and restated warrant forms as exhibits.
Yap Kim Choy filed an amendment on Schedule 13G reporting beneficial ownership in Cyclacel Pharmaceuticals, Inc. common stock totaling 872,000 shares or equivalents, representing 20.76% of the class. The filing states the position consists of 218,000 common shares and 218,000 warrants in each of three series (A, B and C) that together account for the aggregate amount. The filer reports sole voting and dispositive power over the full amount and certifies the securities were not acquired to change or influence control of the issuer. The filing includes links to the amended and restated warrant forms as exhibits.
Yap Kim Choy filed an amendment on Schedule 13G reporting beneficial ownership in Cyclacel Pharmaceuticals, Inc. common stock totaling 872,000 shares or equivalents, representing 20.76% of the class. The filing states the position consists of 218,000 common shares and 218,000 warrants in each of three series (A, B and C) that together account for the aggregate amount. The filer reports sole voting and dispositive power over the full amount and certifies the securities were not acquired to change or influence control of the issuer. The filing includes links to the amended and restated warrant forms as exhibits.
Ong Yee Lung, a director of Cyclacel Pharmaceuticals, Inc., filed an initial Form 3 reporting direct ownership of 218,000 shares of the company’s common stock and receipt of three series of common stock purchase warrants (Series A, B and C), each exercisable into 218,000 shares. Each warrant became exercisable on 06/20/2025 and expires on 06/20/2030, with exercise prices of $7.65, $9.00 and $10.20, respectively. The filing states these warrants were issued under a securities purchase agreement dated 06/20/2025. A previously applicable 4.99% beneficial ownership limitation under each warrant was removed effective 09/01/2025.
Kua Khai Loon, a director of Cyclacel Pharmaceuticals, Inc., reported initial beneficial ownership after a securities purchase agreement dated June 20, 2025. He directly acquired 218,000 shares of the company's common stock and received three tranches of common stock purchase warrants (Series A, B and C), each exercisable to purchase 218,000 shares. Each warrant became exercisable on 06/20/2025 and expires on 06/20/2030 with exercise prices of $7.65, $9.00, and $10.20, respectively. The filing states the 4.99% beneficial ownership limitation under each warrant was removed on 09/01/2025. The Form 3 indicates the reporting person filed as an individual and is identified as a director.
Cyclacel Pharmaceuticals, Inc. director Yap Kim Choy filed an Initial Statement of Beneficial Ownership (Form 3) disclosing an acquisition tied to a June 20, 2025 securities purchase agreement. Mr. Yap acquired 218,000 shares of common stock and received three separate warrant series (Series A, B and C), each to purchase 218,000 shares. The warrants became exercisable on 06/20/2025 and expire 06/20/2030 with exercise prices of $7.65, $9.00 and $10.20, respectively. A beneficial ownership limitation of 4.99% under each warrant was removed on 09/01/2025. The Form 3 lists Mr. Yap as a director and reports direct ownership of the disclosed securities.
Cyclacel Pharmaceuticals, Inc. reported that on September 1, 2025 it entered into amended and restated Series A, B and C common stock purchase warrants. These amendments remove a prior Ownership Limitation that had restricted exercises so holders could not own or vote more than the lower of a Nasdaq-based cap and 4.99% of the company’s common stock before stockholder approval. Board and majority stockholder approval for removing this limit was obtained as described in a Schedule 14C effective July 28, 2025.
The amended Series A warrants allow each holder to purchase 218,000 common shares at $7.65 per share, Series B warrants allow 218,000 shares at $9.00 per share, and Series C warrants allow 218,000 shares at $10.20 per share. Each series now has an expiration date five years from its issuance.
Cyclacel Pharmaceuticals, Inc. changed its independent auditor and disclosed serious funding concerns. On August 22, 2025, the board’s Audit Committee dismissed Bush & Associates CPA LLP and approved the appointment of SFAI Malaysia PLT as the new independent registered public accounting firm for the year ending December 31, 2025.
From November 5, 2024 to August 22, 2025, the company reports no accounting disagreements with Bush, but Bush advised that Cyclacel does not have sufficient funds to complete development and commercialization and had a limited cash balance as of December 31, 2024. Bush indicated this situation raises substantial doubt about Cyclacel’s ability to continue as a going concern.
Cyclacel Pharmaceuticals, Inc. Schedule 13G filed by Yap Kim Choy discloses beneficial ownership of 218,000 shares, representing 9.8% of the class. The filing states these shares are held with sole voting and dispositive power and that they were not acquired to change or influence control of the issuer. The statement identifies the filing as a Schedule 13G disclosure and includes a signature certifying the accuracy of the information.
Cyclacel Pharmaceuticals, Inc. Schedule 13G filed by Ong Yee Lung reports beneficial ownership of 218,000 shares of Cyclacel common stock, representing 9.8% of the class. The filer states sole voting and dispositive power over all 218,000 shares. The filing is submitted under Schedule 13G disclosures and includes a certification that the shares were not acquired to change or influence control of the issuer. Several items (group membership, holdings on behalf of others, and subsidiary/group identification) are marked Not Applicable.